Safety and Efficacy of Phacoemulsification With Trabecular Microbypass Stent W Implantation in Primary Angle-Closure Glaucoma.

Background Investigation of the safety and efficacy of phacoemulsification with trabecular microbypass Stent W implantation in patients with primary angle-closure glaucoma (PACG). Methods Between August and December of 2023, this prospective study evaluated PACG patients who underwent phacoemulsification with iStent inject W implantation. All patients were 18 years and older and were monitored for 6 months after surgery. Changes in intraocular pressure (IOP) and the number of glaucoma medications at 6 months after the surgery were defined as the primary endpoint, while the safety of the iStent inject W implantation in these patients was the secondary endpoint. Results Of the six patients in the study, one was male and five were female, with patient ages ranging from 62 to 83 years. Pre- and postoperative IOP (at 6 months) ranged from 12 to 18 mmHg and 9 to 17 mmHg, respectively, with only one patient exhibiting an increase in the IOP from 12 to 17 mmHg. The number of glaucoma medications decreased in all but one case at six months postoperatively. Neither hyphema nor an IOP spike was observed in the present study. There was no evidence of iStent inject W occlusion or malposition at six months postoperatively in any of the cases. Conclusion In patients with PACG, phacoemulsification with trabecular microbypass Stent W implantation was demonstrated to be a safe and effective procedure.